Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Added to Nasdaq Biotechnology Index

NEW YORK (GenomeWeb News) – Following its semi-annual re-ranking, the Nasdaq Biotechnology Index has added Sequenom to the firms included in the Index.
 
Sequenom’s shares will start trading as part of the Index on Monday, Nov. 19.
 
The firm’s shares have more than doubled since mid-September, following the firm’s announcement that it had licensed technology from Harvard University that it will use to develop a nanopore-based sequencing platform that will be faster and cheaper than currently available technologies. Sequenom’s stock closed at $10.10 in Friday trade on the Nasdaq.
 
Sequenom was one of eight new firms added the Biotech Index, but it was the only non-therapeutics company added. The other seven firms are Beijing Med-Pharm, Cadence Pharmaceuticals, Eurand, Halozyme Therapeutics, Obagi Medical Products, Orexigen Therapeutics, and Theravance.
 
The seven firms dropped from the Biotech Index as a result of the re-ranking include Avanir Pharmaceuticals, Genta, Hollis-Eden Pharmaceuticals, NeoPharm, Northfield Labs, Oscient Pharmaceuticals, and Pharmacyclics.
 
Index criteria include listing on the Nasdaq Global Market or Nasdaq Global Select Market, and meeting minimum requirements for market value, average daily share volume, and seasoning as a public company.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.